Published in Cancer Weekly, March 24th, 1997
Quadramet (Samarium 153-EDTMP) was developed to treat the severe pain associated with cancers that have spread to bone. Based on data from the World Health Organization (WHO), there are more than 30,000 new cases of such metastatic cancers in Canada each year.
Human clinical studies of Quadramet for the treatment of bone pain were conducted at over 40 leading medical institutions throughout North America and Europe. Four of the clinical studies contained in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.